Canaccord Genuity Reiterates on Aegerion Pharmaceuticals as Selling is Overdone

In a report published Tuesday, Canaccord Genuity analyst Salveen Richter reiterated a Buy rating and $110.00 price target on Aegerion Pharmaceuticals (NASDAQ: AEGR ). In the report, Canaccord Genuity noted, “AEGR shares traded down yesterday on a re-setting of near-term expectations on the Juxtapid launch and EPS – to be